Treatment of active Crohn's disease with recombinant human granulocyte-macrophage colony-stimulating factor
Treatment of active Crohn's disease with recombinant human granulocyte-macrophage colony-stimulating factor
复制标题
DOI：
10.1016/s0140-6736(02)11437-1
复制
发表时间：
2002-11-09
期刊：
影响因子：
168.9
通讯作者：
Korzenik, JR
中科院分区：
文献类型：
--
作者：
Dieckgraefe, BK;Korzenik, JR
克罗恩病的治疗旨在进行免疫抑制。然而，与先天性免疫缺陷相关的遗传性疾病常常导致类似克罗恩病的疾病发生。我们进行了一项开放标签的剂量递增试验（每天4 - 8微克/千克），以研究粒细胞 - 巨噬细胞集落刺激因子（GM - CSF）在治疗15例中重度克罗恩病患者中的安全性和可能的益处。没有患者病情恶化。不良事件可以忽略不计，包括轻微的注射部位反应和骨痛。患者在治疗期间的平均克罗恩病活动指数（CDAI）评分显著下降（p
Treatment for Crohn's disease is aimed at immunosuppression. Yet inherited disorders associated with defective innate immunity often lead to development of a Crohn's-like disease. We performed an open-label dose-escalation trial (4-8 mug/kg per day) to investigate the safety and possible benefit of granulocyte-macrophage colony-stimulating factor (GM-CSF) in the treatment of 15 patients with moderate to severe Crohn's disease. No patients had worsening of their disease. Adverse events were negligible and included minor injection site reactions and bone pain. Patients had a significant decrease in mean Crohn's disease activity index (CDAI) score during treatment (p